Lipocine announces financial results for the full year ended december 31, 2024

Salt lake city , march 13, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the year ended december 31, 2024, and provided a corporate update. oral brexanolone lpcn 1154 is an oral formulation of the neuroactive steroid brexanolone that lipocine is developing for the rapid treatment of postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking